Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)

Amylyx Pharmaceuticals has reported Receivables for 4 years, with the latest figure at $188000.0 in Q4 2025.

• On a quarterly basis, Receivables fell 65.63% year-over-year to $188000.0 in Q4 2025; TTM through Dec 2025 was $188000.0, a 65.63% decrease from a year earlier, with the FY2025 full-year figure at $188000.0, down 65.63% from the prior year.
• Receivables was $188000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $232000.0 in the prior quarter.
• The five-year high for Receivables was $40.6 million in Q4 2023, with the low at $137000.0 in Q3 2022.
• Average Receivables over 4 years is $11.9 million, with a median of $3.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Receivables surged 21398.54% in 2023, then sank 98.65% in 2024.
• Over 4 years, Receivables stood at $15.8 million in 2022, then jumped by 156.55% to $40.6 million in 2023, then tumbled by 98.65% to $547000.0 in 2024, then sank by 65.63% to $188000.0 in 2025.
• The last three Receivables figures came in at $188000.0 (Q4 2025), $232000.0 (Q3 2025), and $203000.0 (Q2 2025), per Business Quant data.